ClinicalTrials.gov record
Completed Phase 1 Interventional Results available

Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma

ClinicalTrials.gov ID: NCT03323034

Public ClinicalTrials.gov record NCT03323034. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 2:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Study of Pevonedistat (MLN4924), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors

Study identification

NCT ID
NCT03323034
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Children's Oncology Group
Network
Enrollment
30 participants

Conditions and interventions

Eligibility (public fields only)

Age range
6 Months to 21 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 10, 2018
Primary completion
Sep 29, 2021
Completion
Sep 29, 2024
Last update posted
Oct 21, 2024

2018 – 2024

United States locations

U.S. sites
20
U.S. states
17
U.S. cities
20
Facility City State ZIP Site status
Children's Hospital of Alabama Birmingham Alabama 35233
Children's Hospital Los Angeles Los Angeles California 90027
Children's Hospital of Orange County Orange California 92868
UCSF Medical Center-Mission Bay San Francisco California 94158
Children's Hospital Colorado Aurora Colorado 80045
Children's National Medical Center Washington D.C. District of Columbia 20010
Children's Healthcare of Atlanta - Arthur M Blank Hospital Atlanta Georgia 30329
Lurie Children's Hospital-Chicago Chicago Illinois 60611
Riley Hospital for Children Indianapolis Indiana 46202
Dana-Farber Cancer Institute Boston Massachusetts 02215
C S Mott Children's Hospital Ann Arbor Michigan 48109
University of Minnesota/Masonic Cancer Center Minneapolis Minnesota 55455
Washington University School of Medicine St Louis Missouri 63110
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center New York New York 10032
Cincinnati Children's Hospital Medical Center Cincinnati Ohio 45229
Children's Hospital of Philadelphia Philadelphia Pennsylvania 19104
Children's Hospital of Pittsburgh of UPMC Pittsburgh Pennsylvania 15224
Saint Jude Children's Research Hospital Memphis Tennessee 38105
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center Houston Texas 77030
Seattle Children's Hospital Seattle Washington 98105

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03323034, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 21, 2024 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03323034 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →